These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model. Umemura K, Toshima Y, Nakashima M. Eur J Pharmacol; 1994 Sep 01; 262(1-2):27-31. PubMed ID: 7813575 [Abstract] [Full Text] [Related]
23. Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase. Lee JY, Markland FS, Lucchesi BR. J Cardiovasc Pharmacol; 2013 Feb 01; 61(2):152-9. PubMed ID: 23188127 [Abstract] [Full Text] [Related]
24. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis. Valji K, Arun K, Bookstein JJ. J Vasc Interv Radiol; 1995 Feb 01; 6(1):91-5. PubMed ID: 7703589 [Abstract] [Full Text] [Related]
27. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity. Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Yui Y, Kawai C. J Cardiovasc Pharmacol; 1993 Dec 01; 22(6):834-40. PubMed ID: 7509901 [Abstract] [Full Text] [Related]
40. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. Matsuno H, Uematsu T, Nagashima S, Nakashima M. J Pharmacol Methods; 1991 Jul 01; 25(4):303-17. PubMed ID: 1909407 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]